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Angiotensin II does not increase renal prostaglandin E2 in
response to pressure reduction
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MoRto KURAMOCHI, and TERUO OMAE
Division of Hypertension and Renal Diseases, National Cardiovascular Center, Osaka, Japan
Angiotensin H does not increase renal prostaglandin E2 in response to
pressure reduction. Whether angiotensin II (Ang II) stimulates renal
secretion of prostaglandin E2 (PGE2) synthesized in response to pres-
sure reduction was examined. PGE2 and Ang II in aortic and renal
venous plasma were measured before and during renal arterial constric-
tion in anesthetized dogs, with or without an intrarenal arterial infusion
of an Ang II antagonist, losartan potassium (1 mg/mm), or saralasin (3
gImin). In other anesthetized dogs, two doses of Ang 11(30 and then
300 ng/min) were infused into the renal artery, and plasma Ang II levels
and renal PGE2 secretion were measured. When renal perfusion pres-
sure was reduced to 75 and 45 mm Hg by constriction, the renal
secretion of PGE2 increased seven- and fourfold, respectively. Ang II
levels in the renal venous plasma increased from 6.6 1.8 to 21.7 7.4
and then 48.1 15.3 pg/ml (both P < 0.05) as the pressure decreased.
Neither losartan nor saralasin suppressed the response of renal PGE2
secretion to the pressure reduction. The intrarenal infusion of Ang 11(30
nglmin) elevated the Ang II level in the renal venous plasma from 9.8
4.6 to 33.7 4.2 pg/mI (P < 0.01), but did not increase PGE2 secretion.
The higher dose (300 nglmin) of Ang II increased it, but the Ang II level
in the renal venous plasma was 166 63 pg/ml. These results suggest
that the greater part of the increased renal synthesis of PGE2 in
response to pressure reduction is not mediated by Ang II.
When the renal artery is stenotic unilaterally and the renal
perfusion pressure is reduced, secretion of prostaglandins (PGs)
E2 and '2 from the stenotic kidney is increased [1—4] as the
secretion of renin increases. The increased synthesis of PGs has
been thought to be due to increased levels of angiotensin II
(Ang II) caused by high renin activity [5]. PGE2 and PGI2
stimulate renin release [4, 6] and Ang II stimulates renal
synthesis of the PGs [4, 7, 8] pharmacologically, so PGs and the
renin-angiotensin system may interact in the kidney with renal
arterial stenosis. In the stenotic kidney, PGs further stimulate
renin release, according to studies done with cyclooxygenase
inhibitors [6, 9], but whether Ang II increases PG synthesis is
not yet known, because the Ang II antagonists available have
had agonistic action in certain conditions.
In addition, the degree of pressure reduction (renal arterial
stenosis) giving maximum renal secretion of PGs is different
from the degree giving maximum secretion of renin [10]. This
phenomenon calls for further study of the effect of Ang II on
renal synthesis of PGE2 in response to pressure reduction.
Here, we investigated whether Ang II is the cause of the
increased renal synthesis of PGs that occurs when renal perfu-
sion pressure decreases, using two different kinds of Ang II
antagonists, losartan potassium (DuP 753; new nonpeptide) [11]
and saralasin (peptide).
Methods
Preparation of animals
Adult mongrel dogs of either sex (body wt 12 to 16 kg) were
fed a standard laboratory chow, which was withheld starting 18
hours before the experiments, and were given free access to
water. The dogs were anesthetized with intravenous sodium
pentobarbital (30 mg/kg). The trachea was cannulated and the
dogs were ventilated mechanically with a Harvard respirator
(Model 607). Polyethylene catheters were placed in the right
brachial artery and vein for measurement of blood pressure and
for infusion of saline (1 ml/min) or a drug, respectively. Sys-
temic blood pressure was continuously monitored with a pres-
sure transducer (P231D, Viggo Spectramed) connected to a
catheter, the tip of which was placed in the aorta. A catheter
was inserted into the right femoral artery and the tip was placed
in the abdominal aorta for aortic blood sampling. The left
kidney was exposed through a left flank incision, and all visible
nerve fibers around the renal artery were dissected to prevent
the renal nerves from affecting the actions of the drugs used. An
electromagnetic flow probe was placed around the renal artery,
and the left renal blood flow was continuously recorded with an
electromagnetic flowmeter (Nihon Kohden MFV-3200, Tokyo,
Japan). A 23-gauge curved needle was inserted into the renal
artery just distal to the flow probe for infusion of saline or drug
solutions and for monitoring of the renal perfusion pressure. A
constrictor device was placed around the renal artery proximal
to the flow probe. Graded extraluminal constriction of the renal
artery was produced by the tying of a silk suture tightly around
the vessel, and the suture tension was regulated with a cylin-
drical plastic tube and a screw cock. This device produced
varying degrees of stable stenosis of the renal artery. A poly-
ethylene catheter was inserted into the left ureter so as not to
interfere with the urine flow. The left renal vein was cannulated
via the gonadal vein for collection of renal venous blood. More
than one hour after surgery ended, experiments were started.
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Experimental protocol
Different dogs were used in each experiment.
Assessment of renal secretion of PGE2 and renin and plasma
levels of Ang II in response to decreased renal perfusion
pressure. In six dogs, after control blood sampling from the
aorta and renal vein (8 ml each), renal perfusion pressure was
reduced by the constrictor device in steps from the control
pressure to about 75 and then to about 45 mm Hg; these
pressures are within and below the autoregulatory range of
renal blood flow, respectively. Blood in the two sites was
sampled after 8 minutes of equilibration at each step of pres-
sure. The blood samples were immediately placed in ice-cooled
tubes containing ethylenediaminetetraacetic acid 2 Na (1 mgI
ml). The plasma was separated and assayed for PGE2, Ang II,
and plasma renin activity (PRA). The systemic blood pressure,
renal perfusion pressure, and renal blood flow were serially
monitored during the study. The secretion rate of PGE, was
calculated as: Secretion rate (pg/g of kidney/mm) = [venous
concentration (pg/ml plasma) — arterial concentration (pglml
plasma)] x renal plasma flow (ml/min) ÷ renal weight (g). The
renin secretion rate was also calculated by this formula.
Study with a PG synthesis inhibitor. In another group of six
dogs, after the control sampling of blood, aspirin DL-lysine (54
mg/kg, Venopirin, Green Cross Corp., Osaka, Japan), a syn-
thesis inhibitor of PGs, was injected intravenously. Twenty
minutes later, aortic and renal venous blood was sampled, and
the experiment described above was done as in the first six
dogs.
Ang II infusion study. Ang II (human type; Peptide Institute,
Inc., Osaka, Japan) was infused with an infusion pump into the
left renal artery of five dogs first at the dose of 30 nglmin and
then at the dose of 300 ng/min. (Ang II is the same in humans
and dogs [12]). In the control phase, saline was infused (0.3
ml/min) into the left renal artery and blood was drawn from the
aorta and the left renal vein (8 ml each). The saline was replaced
by Ang II solution at the dose of 30 nglmin, and blood was
sampled from the two sites 8 minutes after the replacement.
Next, saline was used again for the intrarenal infusion for at
least 30 minutes during the recovery phase. After blood sam-
pling from the two sites of the recovery controls, Ang II was
infused at the dose of 300 nglmin and blood sampling was done
eight minutes after the start of the second infusion. The sampled
blood was assayed for PGE2, Ang II, and PRA.
Study with Ang II antagonists. Two kinds of Ang II antago-
nists (peptide and nonpeptide) were used. One was saralasin
([Sar', Ala8]Ang II, Peptide Institute) and the other was losar-
tan potassium (DuP 753: 2-n-butyl-4-chloro-5-hydroxymethyl-
1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole, potas-
sium salt; the gift of Dr. Timmermans, E.I. du Pont de Nemours
& Co.). After control blood sampling, saralasin (3 sgImin, N
6) or losartan (1 mg/mm, N = 5) was infused into the left renal
artery. Twenty minutes after the start of the infusion, aortic and
left renal venous blood was sampled. Then the renal perfusion
pressure was reduced in steps by the constrictor device, and
blood in the two sites was collected as in the first study in this
protocol. The inhibition by saralasin and losartan of Ang II was
checked by monitoring of the renal blood flow before and after
a single injection of Ang 11(50 ng) into the left renal artery. We
decided on the doses of these antagonists based on previous
reports [13—16]. In anesthetized dogs, the intrarenal arterial
infusion of saralasin at 3 jsg/min completely blocks the effect of
Ang II [13], and the intravenous infusion of saralasin at 3 to 10
pg/kg per minute blocks that effect in humans [14]. When given
intravenously, losartan completely blocked the action of Ang II
at 3 mg/kg [15]. For intrarenal arterial infusions, we gave I mg
of losartan per minute.
Measurements of humoral factors
PRA was measured by a radioimmunoassay as reported
elsewhere [17]. The plasma levels of Ang II [18] and PGE2 [9]
were also measured by radioimmunoassays reported elsewhere.
In brief, for the measurement of Ang II, 2 ml of plasma was put
on a Sep-Pak cartridge (Waters Associates, Milford, Massachu-
setts, USA) and the Ang II was eluted with 3 ml of an
80:19.9:0.1 (vol/vol/vol) mixture of methanol, water, and triflu-
oroacetic acid. After the extraction, the Ang II was purified by
high-pressure liquid chromatography and radioimmunoassayed.
For the measurement of PGE2, 2 ml of plasma was put on a
Bond-Elut C-18 cartridge column (200 mg, Analytichem Intl.
Inc., Harbor City, Calilomia, USA) and the PGE2 was eluted
with ethyl acetate. Next, a Bond-Elut silica column (500 mg,
Analytichem) was used for further purification of PGE2. After
the purification, the samples were assayed with a ['251]PGE2
radioimmunoassay kit (New England Nuclear Corp., Boston,
Massachusetts, USA).
Statistical analysis
Results are expressed as means SEM. The values for PGE2,
PRA, Ang II, renal blood flow, and blood pressure before and
after treatment (administration of aspirin or an Ang II antago-
nist and pressure reduction) were compared by randomized
block analysis of variance followed by Student-Newman-
Keuls's test for simultaneous multiple comparison. Ang II
levels in aortic and renal venous plasma were compared by
Student's paired t-test. Secretion rates of renin in the groups
with and without aspirin treatment were compared by Student's
t-test.
Results
Renal secretion of PGE2 and renin, and Ang II levels in
plasma
In anesthetized dogs, the basal secretion rate of PGE2 was
14.7 3.6 pg/g kidney per minute, and the PGE2 secretion was
increased about seven- and fourfold when renal perfusion
pressure was reduced to 75 and 45 mm Hg, respectively (Fig.
lA). The amount of PGE2 secretion at the perfusion pressure of
75 mm Hg was significantly larger than that at the pressure of 45
mm Hg. Aspirin DL-lysine completely inhibited the secretion of
PGE2 in response to pressure reduction (Fig. 1A). Basal renin
secretion was 1.4 0.7 ng/g kidney per minute, and the
secretion increased depending on the degree of the reduction of
renal perfusion pressure (Fig. 1B). The increase in the renin
release was significantly inhibited by aspirin (Fig. 1B). Basal
levels of Ang II in aortic and left renal venous plasma were 12.8
3.2 and 6.6 1.8 pglml, respectively. The Ang II level in the
renal venous plasma was significantly lower (P <0.05) than the
level in the aortic plasma. When the perfusion pressure was
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Fig. 1. Renal secretion of prostaglandin E2
(PGE2; A) and renin (B) in response to
pressure reduction. The open columns show
values without any drugs. The dotted columns
(to the right in each pair of columns) show
values with an intravenous injection of aspirin
DL-lysine (ASP, 54 mg/kg) except for
"Control", sampled before the injection.
RPP, renal perfusion pressure. *p < 0.05 and
< 0.01 compared with the controls. §P <
0.05 compared with the values in response to
a renal perfusion pressure of 75 mm Hg. #P
<0.05 and ##P < 0.01 compared with the
values 20 mm after treatment with ASP.
Fig. 2. Angiotensin II (Ang II) levels in aortic
plasma (U) and renal venous plasma (u). A.
Ang IL levels in response to decreased renal
perfusion pressure. B. Changes in plasma
levels of Ang II when authentic Ang II was
injected into the renal artery at the dose of 30
and then 300 ng/min. Abbreviations are: Ao,
aortic plasma; V, renal venous plasma; RPP,
renal perfusion pressure. *D < 0.05 and **
<0.01 compared with the controls or
recovery. #P < 0.05 compared with the
values in response to renal perfusion pressure
of 75mm Hg.
reduced in steps, the Ang II levels at the two sites were
significantly elevated in the same way (Fig. 2A).
Ang II infusion study
Figure 2B shows changes in the Ang II levels in aortic and
renal venous plasma after the intrarenal arterial infusion of Ang
II. The basal Ang II levels were 16.5 7.3 and 9.8 4.5 pglml
in the aortic and the renal venous plasma, respectively. The
venous plasma levels were lower (P < 0.05) than the aortic
plasma levels. When Ang II was infused at the dose of 30
ng/min, Ang II levels at the two sites increased significantly; the
level in the renal venous plasma was 33.7 4.2 pg/ml. This
value was close to the values after an increase in response to
pressure reduction (Fig. 2A). However, the renal secretion of
PGE2 was not stimulated by the Ang II at 30 ng/min; the change
wasfrom9.l 3.Oto 13.3 5.6pg/gkidneyperminute(Fig. 3).
The higher dose of Ang 11(300 ng/min) increased the Ang II
level in the renal venous plasma to 166 63 pg/ml. This large
amount of Ang II somewhat increased the renal secretion of
PGE2, from 11.5 3.2 to 37.9 14.9 pg/g kidney perminute (P
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Fig. 3. Renal secretion of prostaglandin E2 (PGE2) before and during
intrarenal arterial infusion of angiotensin II (Ang II). 4P < 0.05
compared with recovery.
< 0.05; Fig. 3). Changes in renal blood flow caused by the
infusion of Ang II were from 3.4 0.3 to 2.8 0.3 mug kidney
per minute (P < 0.05) at the dose of 30 ng/min and then from 3.5
0.3 to 2.3 0.2 nullg kidney per minute (P < 0.01) at the dose
of 300 nglmin. The blood flow was measured before and 8 mm
after the start of infusion at each dose, as described in Methods.
Study with Ang II antagonists
It was confirmed beforehand that either saralasin or losartan
completely blocked the action of a single injection of Ang II in
decreasing the renal blood flow. The effects of saralasin and
losartan on the renal secretion of POE2 in response to pressure
reduction are shown in Figure 4. The intrarenal arterial infusion
of either Ang II antagonist did not inhibit the PGE2 secretion
caused by the reduction in renal perfusion pressure. The
secretion rate of PGE2 was higher (P < 0.01) when the
perfusion pressure was 75 mm Hg than when it was 45 mm Hg,
as in the experiment without Ang II antagonists. The increase in
renin secretion in response to pressure reduction was not
affected by saralasin or losartan, either (Fig. 5).
Hemodynamic changes
Table 1 shows hemodynamic changes in response to de-
creased renal perfusion pressure with or without the drugs.
When the renal perfusion pressure was reduced to about 75 mm
Hg, renal blood flow was not changed significantly, but in dogs
given aspirin beforehand, the flow decreased slightly (P <0.05);
in contrast, the renal blood flow increased (P < 0.01 and 0.05)
in dogs given either saralasin or losartan. When the perfusion
pressure was reduced to 45 mm Hg, the renal blood flow
decreased to nearly half in all test groups. Systemic blood
pressure in the group given no drug and the group given aspirin
increased when renal perfusion pressure was decreased to 45
mm Hg. When an Ang II antagonist was given before and during
the decrease in the renal perfusion pressure, this increase was
blocked.
Control Ang II RPP RPP
Antagonist 75 mm Hg 45 mm Hg
Intrarenal arterial infusion
Fig. 4. Renal secretion of prostaglandin E2 (PGE2) in response to
decreased renal perfusion pressure (RPP) during treatment with an
angiotensin II (Ang ii) antagonist, saralasin (D, 3 pgImin) or losartan
(i, DuP 753, 1 mg/mm). *D < 0.05 and ** < 0.01 compared with the
controls. #P < 0.05and ##P <0.01 compared with the values after the
start of injection of the Ang II antagonist. §P < 0.01 compared with
values in response to RPP of 75 mm Hg.
Discussion
We found no evidence for a contribution by Ang II to
increased renal synthesis of POE2 in response to pressure
reduction.
Pharmacologically, Ang II stimulates the renal synthesis of
PGE2 both in vivo [4, 7, 8, 19] and in vitro [20]. Thus, it has
been believed that the renal secretion of PGE2 in response to
decreased perfusion pressure is due to increased Ang II,
occurring via the increased release of renin [5]. Pathophysio-
logically, however, this might not actually occur, because there
is a dissociation between the peaks of renal secretion of PGE2
and renin in response to the reduction of renal perfusion
pressure. In anesthetized dogs, renal secretion of PGs is max-
imum when the renal perfusion pressure is 60 to 77 mm Hg,
which is the borderline pressure needed to maintain the renal
blood flow, but the ipsilateral release of renin increases in
proportion to the pressure reduction [10]. This phenomenon
was seen again in this study. There are both PG-dependent and
PG-independent (baroreceptor) mechanisms of renin release in
response to decreased renal perfusion pressure [6, 20]. So, the
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Control Ang II RPP RPP
Antagonist 75 mm Hg 45 mm Hg
Control
Treatment
with a
drug
First
pressure
reduction
Second
pressure
reduction
Renal perfusion
pressure
(mean) mm Hg
Nodrug
Aspirin
Saralasin
124±4
120 3
122 6
126 3
122 5
74l"
78 31)173 1
452"
48 2""
1b.d
Losartan 126 6 126 5 2,d
Renal blood flow
mug/mm
No drug
Aspirin
Saralasin
3.2 0.3
3.3 0.4
3.0 0.3
2.9 0.5
3.1 0.4
3.5 0.32.6 0.?
4.1 0.5
1.8 0.2"
1.42.4 0.3"
Losartan 3.7 0.3 4.0 0.4 4.7 0.5 2.7 0.3""
Systemic blood
pressure
(mean) mm Hg
Nodrug
Aspirin
124±4
120 3 126 2"
126±4
128 3"
140±5"
132 3""
Saralasin 122 6 122 5 121 5 121 5
Losartan 126±6 126±5 126±5 127±5
Values are means 5EM. These data were compared by randomized
block analysis of variance followed by Student-Newman-Keuls's test
for simultaneous multiple comparison.
a p < 0.05 and "P C 0.01 relative to control values
C P C 0.05 and "P C 0.01 relative to values for treatment with the
drug before pressure reduction
Intrarenal arterial infusion
Fig. S. Renal secretion of renin in response to decreased renal perfu-
sion pressure (RPP) during treatment with an angiotensin II (Ang II)
antagonist, saralasin (fl, 3 ,ug/mitt) or tosartan (0, DuP 753, 1 mg/mm).
*p < 0.05 and ** C 0.01 compared with the controls. lIP C 0.05 and
##P C 0.01 compared with the values after the start of an injection of
the Ang II antagonist. §*P C 0.01 compared with the values in response
to RPP of 75 mm Hg.
phenomenon does not suggest that PGE2 is not involved in the
accelerated release of renin. The results reported here for the
study with aspirin also confirmed the existence of those two
mechanisms of PG-dependent and PG-independent renin re-
lease (Fig. lB). They are not consistent with Ang II stimulating
PGE2 synthesis if the Ang II level in the kidney increases (as
renin release does) in proportion to the pressure reduction.
Our study showed that the increase in Ang II in the renal
venous plasma was parallel to the increase in renin secretion.
However, the Ang II concentrations in renal venous plasma
were lower than those in the aortic plasma (Fig. 2A). This is
consistent with the previous findings in anesthetized dogs [211
and also in humans [22]. This phenomenon may reflect the
metabolism of Ang II in the kidney being greater than its
production; more than 90% of circulating Ang II is metabolized
in the kidney, but Ang II formed within the kidney is a
consequence of increased intrarenal Ang I generation due to
increased renin release [211. Thus, the changes in the Ang II
level in renal venous plasma might reflect the renal synthesis
and metabolism of Ang II, and we therefore used intrarenal Ang
II infusion to investigate the amount of Ang II needed to
stimulate PGE2 synthesis by measurement of Ang II in the renal
venous plasma. The continuous infusion of Ang 11(30 ng/min)
into the kidney decreased the renal blood flow by only 18%, and
increased the renal venous Ang II to a level higher than the level
reached in response to the reduction of renal perfusion pressure
to 75 mm Hg. The amount of Ang II infused did not increase the
renal secretion of PGE2. In previous studies [7, 8, 19] and in this
study as well, pharmacological, not physiological, amounts of
Ang II were needed for the stimulation of renal PGE2 synthesis.
In anesthetized and laparatomized dogs, basal renal PGE2
production is stimulated without renal arterial constriction, and
the amount of Ang II that would need to be infused to increase
renal PGE2 would be larger than in conscious dogs not under-
going surgery. But when renal perfusion pressure was 75 mm
Hg, renal PGE2 production was much larger than that caused by
Ang II infusion. In addition, renal venous plasma levels of Ang
II at that renal perfusion pressure were much less than those
caused by exogenous Ang II infused at 300 ng/min. However,
the concentration of Ang II in the renal venous plasma may not
necessarily be proportional to the effective concentrations at
the sites of production and action. A further possibility is that
tissue rather than circulating Ang II is responsible for physio-
logical actions such as the stimulation of PG synthesis [23—25].
Thus, results from the above experiment could not rule out the
possibility of a pathophysiological role of Ang II in PG stimu-
lation in response to pressure reduction.
Neither kind of Ang II antagonist that we used suppressed the
renal synthesis of PGE2 in response to pressure reduction. The
doses of saralasin and losartan were high enough to inhibit the
action of Ang II, according to results of reported studies
[13—16], and both drugs acted as antagonists when Ang II was
a
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Table 1. Hemodynamic changes caused by renal arterial constriction
with and without treatment with aspirin or an angiotensin II
antagonist
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given as a bolus injection. Further, both losartan and saralasin
prevented the elevation of blood pressure caused by renal
arterial constriction (Table 1). Recently, it has been reported
that there are two subtypes of Ang II receptors, AT1 and AT2
[26, 27]. The receptors that mediate Ang-IT-induced vasocon-
striction and PGE2 synthesis are all of the AT1 type [28].
Losartan is a selective AT1 receptor antagonist, and saralasin is
a nonselective one. The antagonizing action of these drugs on
the stimulation of PGE2 synthesis by Ang II has already been
demonstrated [281. We also found that losartan and saralasin
blocked the effect of an intrarenal arterial Ang II infused in a
large dose on the stimulation of renal PGE2 production (data not
shown). In our study, the renal site of PGE2 synthesis in
response to pressure reduction was not identified, but the
antagonists to Ang II seemed to reach the site that was
stimulated by Ang II, as aspirin did. Therefore, when levels of
Ang II are increased in response to pressure reduction, if renal
PGE2 production increases because of the pathophysiological
increase in Ang II, these Ang II antagonists must suppress the
release of PGE2 from the stenotic kidney. These findings
suggest that Ang II does not stimulate the renal synthesis of
PGE2 that occurs in response to pressure reduction, or else that
it does not have a major role in such synthesis of PGE2. The
studies with the two kinds of Ang II antagonists used here
provided more direct evidence of the effects of Ang II on PG
synthesis than studies that might be done with renin inhibitors
or angiotensin converting enzyme inhibitors (the latter influence
bradykinins).
Losartan and saralasin did not affect renin release in response
to pressure reduction, which was consistent with a previous
report [131. When renal perfusion pressure was reduced to
about 75 mm Hg (the borderline of the autoregulation of renal
blood flow), aspirin decreased the renal blood flow, but the Ang
II antagonists increased it. These results support that the
increase in renal PG is independent of any increase in Ang II in
response to pressure reduction.
Ang II does, of course, have a physiological effect in stimu-
lating PG synthesis. However, our study suggests that when
renal perfusion pressure is reduced, increased renal PGE2
further stimulates renin release, but that the greater part of
PGE2 seems to be independent of Ang II.
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